| Gene symbol | MIR122 | Synonyms | MIR122A, MIRN122, MIRN122A, hsa-mir-122, miRNA122, miRNA122A, mir-122 | Type of gene | ncRNA |
| Chromosome | 18 | Map location | 18q21.31 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | microRNA 122 | ||||
| GTO ID | GTC3977 |
| Trial ID | NCT02749331 |
| Disease | Neuroendocrine Tumor |
| Altered gene | miR122 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | DNA oncolytic virus |
| Treatment | AdVince|Ad5PeptideTransductionDomain(PTD)(CgA-E1AmiR122) |
| Phase | Phase1|Phase2 |
| Recruitment status | Unknown |
| Title | Study of Recombinant Adenovirus (AdVince) in Patients With Neuroendocrine Tumors; Safety and Efficacy |
| Year | 2016 |
| Country | Sweden |
| Company sponsor | Uppsala University |
| Other ID(s) | VIRUSNET201401|2014-000614-64 |
| Vector information | |||||||||||
|
|||||||||||
| Cohort1: dose level 1 | |||||||
|
|||||||
| Cohort2: dose level 2 | |||||||
|
|||||||
| Cohort3: dose level 3 | |||||||
|
|||||||
| Cohort4: dose level 4 | |||||||
|
|||||||